User profiles for Manish Soneja
 | manish sonejaAIIMS, New Delhi Verified email at aiims.edu Cited by 6085 |
[HTML][HTML] Chloroquine and hydroxychloroquine for the treatment of COVID-19: a systematic review and meta-analysis
Background There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and
chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain…
chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain…
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine that has been
deployed in India. The results of the phase 3 trial have shown clinical efficacy of BBV152. We …
deployed in India. The results of the phase 3 trial have shown clinical efficacy of BBV152. We …
Post COVID-19 sequelae: A prospective observational study from Northern India
Post COVID-19 sequelae are a constellation of symptoms often reported after recovering
from COVID-19. There is a need to better understand the clinical spectrum and long-term …
from COVID-19. There is a need to better understand the clinical spectrum and long-term …
[HTML][HTML] HIV & immune reconstitution inflammatory syndrome (IRIS)
Antiretroviral therapy (ART) initiation in HIV-infected patients leads to recovery of CD4+ T
cell numbers and restoration of protective immune responses against a wide variety of …
cell numbers and restoration of protective immune responses against a wide variety of …
[HTML][HTML] Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India
…, A Choudhary, M Brijwal, M Soneja… - Indian Journal of …, 2020 - journals.lww.com
Methods: This was a prospective, single-centre collection of data regarding epidemiological,
demographic, clinical and laboratory parameters, management and outcome of COVID-19 …
demographic, clinical and laboratory parameters, management and outcome of COVID-19 …
[HTML][HTML] Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
As of February 29, 2020, more than 85,000 cases of coronavirus disease 2019 (COVID-19)
have been reported from China and 53 other countries with 2,924 deaths. On January 30, …
have been reported from China and 53 other countries with 2,924 deaths. On January 30, …
[HTML][HTML] ACE2 protein expression in lung tissues of severe COVID-19 infection
…, S Arava, P Das, AR Mridha, G Singh, M Soneja… - Scientific reports, 2022 - nature.com
Angiotensin-converting enzyme 2 (ACE2) is a key host protein by which severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) enters and multiplies within cells. The level of …
syndrome coronavirus-2 (SARS-CoV-2) enters and multiplies within cells. The level of …
[HTML][HTML] Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR …
Background The objectives of the study were to compare the performance of line probe
assay (GenoType MTBDRplus) with solid culture method for an early diagnosis of multidrug …
assay (GenoType MTBDRplus) with solid culture method for an early diagnosis of multidrug …
Comparison of high-flow nasal cannula and noninvasive ventilation in acute hypoxemic respiratory failure due to severe COVID-19 pneumonia
BACKGROUND: Efficacy of high-flow nasal cannula (HFNC) over noninvasive ventilation (NIV)
in severe coronavirus disease 2019 (COVID-19) pneumonia is not known. We aimed to …
in severe coronavirus disease 2019 (COVID-19) pneumonia is not known. We aimed to …
Risk factors for Coronavirus disease-associated mucormycosis
Background The epidemiology of the Coronavirus-disease associated mucormycosis (CAM)
syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden …
syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden …